Original Article

The Utilization Evaluation of Intravenous Pantoprazole for Stress Ulcer Prophylaxis in a Major Teaching Hospital

Abstract

Background: Proton pump inhibitors (PPIs) are one of the first-line drugs for acid-dependent diseases. Inappropriate use of PPIs, especially the Intravenous (IV) formula of pantoprazole, can result in excessive cost. This study aimed to evaluate IV pantoprazole usage's appropriateness and optimize its use in accordance with guidelines at Razi educational and remedial center, Rasht, Iran. Methods: This cross-sectional study was executed in five months among 344 patients of Razi hospital who received IV pantoprazole for stress ulcer prophylaxis (SUP). Demographic data, route and doses of pantoprazole, risk factors for stress ulcer, and other related medical data were recorded. In addition, the appropriate use of IV pantoprazole was measured according to recommendations arranged by this center and the American Society of Health-System Pharmacists. Results: Out of 197 patients who received SUP with an appropriate indication, 183 patients (92.9%) were able to tolerate the drug orally, and only 14 patients (7.1%) had an indication for receiving IV pantoprazole. There was a significant difference between patients who received SUP with an indication regarding having or not having an indication for IV pantoprazole (P = 0.007). 5029 vials (96.5%) with a cost of 17,822 US dollars were used inappropriately and imposed an additional cost on the health care system. Conclusion: This study presented that the majority of IV pantoprazole use in this center was not well-matched with guidelines in most cases, containing appropriate indication and right dosing. In order to prescribe this drug as SUP, it is necessary to be more careful about the criteria for prescribing and conforming the prescribed drug and the prescribed dose to the relevant instructions.

1.Vazin A, Karimzadeh I, Karamikhah R, Oveisi Z, Mohseni S, Keykhaee M, et al. Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital. BMC Health Serv Res. 2018;18(1):815.
2.Moore T, Bykov A, Savelli T, Zagorski A. Guidelines for implementing drug utilization review programs in hospitals. Management Sciences for Health, Arlington. 1997.
3.Bowman L. Drug use evaluation is DUE: healthcare utilization evaluation is over-DUE. Hospital Pharmacy. 1996;31(4):347-53.
4.Sacristén JA, Soto J. Drug utilisation studies as tools in health economics. Pharmacoeconomics. 1994;5(4):299-312.
5.Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother. 2002;36(12):1929-37.
6.Pang SH, Graham DY. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers. Therap Adv Gastroenterol. 2010;3(1):11-22.
7.Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122-9.
8.Kazberuk M, Brzosko S, Hryszko T, Naumnik B. Overuse of proton pump inhibitors and its consequences. Postepy Hig Med Dosw (Online). 2016;70:1112-6.
9.Khamas SS, Mirbagheri I, Moghadam AD, Jafari A, Ashouri A. Evaluation of albumin utilization in a major teaching hospital in iran before and after guideline implementation. J Pharm Care. 2021;9(2):67-73.
10.Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk ofClostridium difficileInfection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. Am J Gastroenterol. 2012;107(7):1011-9.
11.Trikudanathan G, Israel J, Cappa J, O’sullivan D. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients–a systematic review and meta‐analysis. Int J Clin Pract. 2011;65(6):674-8.
12.McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104:S5-S9.
13.Khalili H, Huang ES, Jacobson BC, Camargo CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344.
14.Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047-56.
15.Bazan NS, Farid SF, Baines DL. Impact of clinical pharmacists on adherence to stress ulcer prophylaxis protocol in critically ill Egyptian patients: a comparative study. Drugs & Therapy Perspectives. 2021;37(1):35-43.
16.Khamas SS, Jafari A, Ramezanzadeh E. Drug-drug interactions in kidney transplant patients with coronavirus disease 2019: A report of two cases and literature review. Iranian Red Crescent Medical Journal. 2021;23(3).
17.Armstrong T, Coursin D, Devlin J, et al. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm. 1999;56(4):347-79.
18.Moradi M, Raeesi S, Sepehri Z. Audit of IV pantoprazole: pattern of administration and compliance with guideline in a teaching hospital. Springer Plus. 2016;5(1):1-8.
19.Khalili H, Dashti-Khavidaki S, Talasaz AHH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16(2):114-21.
20.Masood U, Sharma A, Bhatti Z, Carroll J, Bhardwaj A, Sivalingam D, et al. A successful pharmacist-based quality initiative to reduce inappropriate stress ulcer prophylaxis use in an academic medical intensive care unit. Inquiry. 2018;55:0046958018759116.
21.Churi S, Jogani A. Prospective assessment of prescribing pattern of intravenous proton pump inhibitors in an Indian Tertiary-Care Teaching Hospital. Indian Journal of Pharmacy Practice. 2014;7(4):3.
22.Mousavi M, Dashti-Khavidaki S, Khalili H, Farshchi A, Gatmiri M. Impact of clinical pharmacy services on stress ulcer prophylaxis prescribing and related cost in patients with renal insufficiency. Int J Pharm Pract. 2013;21(4):263-9.
23.Dangler M, Ochs L, White R. Assessing the appropriate use of proton pump inhibitors in a veteran outpatient population. Fed Pract. 2013;30:21-5.
24.Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. New Engl J Med. 2018;378(26):2506-16.
25.Alqudah M, Al-Azzam S, Alzoubi K, Alkhatatbeh M, Rawashdeh N. Overuse of proton pump inhibitors for stress ulcer prophylaxis in Jordan. Sepsis. 2016;4(2):1-6.
26.Gharebaghi N, Valizade Hasanloei MA, Hasan Adeli S, Mansuri Zangir SA, Rasuli J. Efficacy of education with American Society of Health system Pharmacists guidelines on the prevention of stress ulcer. Tehran University Medical Journal. 2014;71(10).
27.Craig D, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM. 2010;103(5):327-35.
28.Sohrevardi S-M, Vahidi A, Mosadegh M-H, Dehghani-Tafti A, Dadollahi A. Evaluation of Prescriptions and Use of Intravenous Pantoprazole in General Wards and Intensive Care Unit of Shahid Sadoughi Hospital in Yazd. J Pharm Care. 2015;3(1-2):7-10.
29.Khamas SS, Jafari A, Mokhtari G, Ashouri A, Lebadi M. Evaluation of Potential Drug-Drug Interactions among Patients of the Nephrology and Kidney Transplant Wards of a Major Teaching Hospital in Iran. Journal of Pharmaceutical Research International. 2021:66-78.
30.Freedberg DE, Salmasian H, Abrams JA, Green RA. Orders for intravenous proton pump inhibitors after implementation of an electronic alert. JAMA Intern Med. 2015;175(3):452-4.
31.Buckley MS, Park AS, Anderson CS, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med. 2015;128(8):905-13.
Files
IssueVol 10, No 3 (Summer 2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v10i3.10793
Keywords
Drug Utilization Evaluation Pantoprazole Guideline Implementation Stress Ulcer Prophylaxis Cost
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Shahbazi Khamas S, Darvishi F, Taghvaye-Masoumi H, Rafiei E, Jafari A. The Utilization Evaluation of Intravenous Pantoprazole for Stress Ulcer Prophylaxis in a Major Teaching Hospital. J Pharm Care. 2022;10(3):128-135.